Table 1.
Physician use of breast and/or ovarian cancer risk assessment and screening tools.
| Family Medicine n (%) |
Internist n (%) |
OB/GYN n (%) |
Total n (%) |
|
|---|---|---|---|---|
| Discussion of Cancer Family History | ||||
| Used | 246 (98.4%) | 235 (94.0%) | 246 (98.4%) | 727 (96.9%) |
| Not used | 4 (1.6%) | 13 (5.2%) | 3 (1.2%) | 20 (2.7%) |
| Not familiar with this assessment | 0 (0%) | 2 (0.8%) | 1 (0.4%) | 3 (0.4%) |
| Breast Exam | ||||
| Used | 212 (84.8%) | 200 (80.0%) | 241 (96.4%) | 653 (87.1%) |
| Not used | 38 (15.2%) | 48 (19.2%) | 7 (2.8%) | 93 (12.4%) |
| Not familiar with this assessment | 0 (0%) | 2 (0.8%) | 2 (0.8%) | 4 (0.5%) |
| Mammogram | ||||
| Used | 248 (99.2%) | 240 (96.0%) | 238 (95.2%) | 696 (92.8%) |
| Not used | 2 (0.8%) | 9 (3.6%) | 7 (2.8%) | 18 (2.4%) |
| Not familiar with this assessment | 0 (0%) | 1 (0.4%) | 1 (0.4%) | 2 (0.3%) |
| Breast Cancer Risk Assessment Tool (e.g., Gail Model, BOADICEA, Claus, BRCAPRO, Cuzick-Tyrer)* | ||||
| Used | 110 (44.0%) | 104 (41.7%) | 168 (67.2%) | 382 (50.9%) |
| Not used | 88 (35.2%) | 97 (38.8%) | 59 (23.6%) | 244 (32.5%) |
| Not familiar with this assessment | 52 (20.8%) | 49 (19.6%) | 23 (9.2%) | 124 (16.5%) |
| Genetic Testing for BRCA1 or BRCA2* | ||||
| Used | 114 (45.6%) | 128 (51.2%) | 202 (80.8%) | 444 (59.2%) |
| Not used | 133 (53.2%) | 119 (47.6%) | 48 (19.2%) | 300 (40.0%) |
| Not familiar with this assessment | 3 (1.2%) | 3 (1.2%) | 0 (0%) | 6 (0.8%) |
| Multi-Gene Testing* | ||||
| Used | 62 (24.8%) | 68 (27.2%) | 130 (52.0%) | 260 (34.7%) |
| Not used | 146 (58.4%) | 153 (61.2%) | 101 (40.4%) | 400 (53.3%) |
| Not familiar with this assessment | 42 (16.8%) | 29 (11.6%) | 19 (7.6%) | 90 (12.0%) |
*
Indicates significant difference between provider types (p≤ 0.05)